We are live on
!
Find out more
NC
Nexthera Capital Portfolio holdings
AUM
$120M
1-Year Est. Return
10.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.49%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$607M
AUM Growth
+$64.8M
(+12%)
Cap. Flow
+$73M
Cap. Flow
% of AUM
12.03%
Top 10 Holdings %
Top 10 Hldgs %
61%
Holding
61
New
22
Increased
13
Reduced
4
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$22M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$19.8M |
| 3 |
Corcept Therapeutics
CORT
|
+$19.4M |
| 4 |
Pacira BioSciences
PCRX
|
+$17M |
| 5 |
AstraZeneca
AZN
|
+$16.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$19.5M |
| 2 |
ABLX
Ablynx NV
ABLX
|
+$15.9M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$11M |
| 4 |
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
|
+$9.16M |
| 5 |
Viatris
VTRS
|
+$8.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
| $175M | 28.89% |
2,000,000
| – | – |
|
|
AGN
2
DELISTED
Allergan plc
AGN
| $41.8M | 6.89% |
248,620
+40,749
| +20% | +$6.84M |
|
|
3
Bristol-Myers Squibb
BMY
$126B
| $21.7M | 3.57% |
+342,399
| New | +$22M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.4B
| $21M | 3.46% |
259,235
+95,238
| +58% | +$8.17M |
|
|
SHPG
5
DELISTED
Shire pic
SHPG
| $20.8M | 3.43% |
139,543
-22,406
| -14% | -$3.08M |
|
6
Insmed
INSM
$23.3B
| $20.7M | 3.41% |
918,523
+419,602
| +84% | +$11M |
|
|
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
| $19M | 3.13% |
+362,974
| New | +$19.8M |
|
|
8
Corcept Therapeutics
CORT
$10.4B
| $17.2M | 2.83% |
+1,045,196
| New | +$19.4M |
|
|
9
AstraZeneca
AZN
$261B
| $16.9M | 2.79% |
+242,000
| New | +$16.8M |
|
|
IMMU
10
DELISTED
Immunomedics Inc
IMMU
| $15.8M | 2.6% |
1,081,410
+676,882
| +167% | +$11.1M |
|
|
DOVA
11
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $15.4M | 2.54% |
568,243
+115,211
| +25% | +$3.45M |
|
|
GBT
12
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $15.2M | 2.51% |
315,147
+3,631
| +1% | +$203K |
|
|
SGMO
13
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $14.9M | 2.46% |
786,376
+77,832
| +11% | +$1.66M |
|
|
14
Pacira BioSciences
PCRX
$1.02B
| $14.9M | 2.46% |
+478,620
| New | +$17M |
|
15
Gyre Therapeutics
GYRE
$670M
| $13.9M | 2.29% |
71,817
+30,327
| +73% | +$5.66M |
|
|
CLVS
16
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $12.8M | 2.11% |
242,600
+9,400
| +4% | +$548K |
|
|
SAGE
17
DELISTED
Sage Therapeutics
SAGE
| $12.6M | 2.07% |
78,227
+22,393
| +40% | +$3.8M |
|
18
Heron Therapeutics
HRTX
$86.9M
| $11.3M | 1.86% |
+409,000
| New | +$9.28M |
|
|
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
| $11.1M | 1.82% |
852,686
+316,118
| +59% | +$3.93M |
|
|
20
Viatris
VTRS
$20.1B
| $10.7M | 1.77% |
261,000
-209,296
| -45% | -$8.92M |
|
|
CLLS
21
Cellectis
CLLS
$279M
| $10.5M | 1.73% |
+332,754
| New | +$10.5M |
|
|
AKRX
22
DELISTED
Akorn Inc
AKRX
| $9.44M | 1.55% |
+504,503
| New | +$13.7M |
|
|
23
CALL
BioMarin Pharmaceuticals
BMRN
$11.4B
| $8.73M | 1.44% |
107,700
+4,100
| +4% | +$352K |
|
24
Arrowhead Research
ARWR
$12.2B
| $8.03M | 1.32% |
+1,114,097
| New | +$6.86M |
|
|
STML
25
DELISTED
Stemline Therapeutics, Inc.
STML
| $8.01M | 1.32% |
+523,624
| New | +$8.16M |
|
Similar funds
KAM
VCP
PFC
FCA
TA
EBIM
BCM
ACP
Nexthera Capital's Q1 2018 Portfolio in Review
As of Q1 2018, Nexthera Capital held 61 positions worth $607M, up 12% from $542M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Nexthera Capital deployed $73M of net new capital in Q1 2018, opening 22 new positions and adding to 13 existing holdings. Its largest new stake was Bristol-Myers Squibb: 342,399 shares worth $21.7M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 48% a quarter earlier.
On the sell side, the largest reduction was Viatris, an estimated $8.92M trimmed.
- Nexthera Capital's largest Q1 2018 buy was Bristol-Myers Squibb: 342,399 shares worth $21.7M.
- Nexthera Capital added most to Immunomedics Inc in Q1 2018, an estimated $11.1M increase.
- Nexthera Capital's biggest Q1 2018 reduction was Viatris, cutting an estimated $8.92M.
- Nexthera Capital fully exited Merck in Q1 2018, selling an estimated $19.5M.
- Nexthera Capital's ten largest holdings make up 61% of its $607M portfolio in Q1 2018.
- Nexthera Capital opened 22 new positions and closed 21 in Q1 2018.
- Nexthera Capital's portfolio value rose 12% quarter-over-quarter to $607M.
Based on Nexthera Capital's 13F filing for Q1 2018, filed 15 May 2018.